FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (Celularity), a regenerative and cellular medicine company developing placental-derived allogeneic cell...
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the Company), a regenerative medicine company developing placental-derived allogeneic cell therapies and...
FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a regenerative medicine company developing placental-derived allogeneic cell therapies and...
CELU Announces Net Sales Trending Ahead of Expectations for 1Q '24; Implements Planned '24 SG&A Reductions & Mfg. Ramp for Advanced Biomaterial Products
FLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and advanced...
Celularity Receives HCPCS Q Code Approval from the U.S. Centers
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (Celularity), a regenerative medicine company developing placental-derived allogeneic cell therapies and...
Celularity CEO to Present on Cell Therapy™s Potential
Celularity CEO to Present Keynote Address
Celularity to Present Data Showing Cancer Tumor Reduction by Cell Therapy